GLP-1 pioneer and Taubman Scholars
to headline Taubman Institute 2025 Spring Symposium May 7

Headlines have been dominated in recent months by a new class of drugs, like Ozempic and Mounjaro, based on gastrointestinal hormones that include GLP-1, and their ability to control Type 2 diabetes without insulin while reducing body weight.

But while these positive effects may have been news to many, Dr. Richard DiMarchi was helping lay the foundation for their emergence for the past 40 years. Dr. DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University. His research has championed the biosynthesis and chemical optimization of macromolecules, such as peptides and proteins, with enhanced therapeutic properties. He has spent much of his career focused on improving the lives of individuals with diabetes, and in more recent decades, obesity.

He will headline the Taubman Institute Spring Symposium on May 7 at the Kahn Auditorium in the BSRB.
Posters 8-9:30am, talks 9:30am-12:30pm. All welcome at no charge. Registration requested for catering.
Click here to register for the May 7 Taubman Institute Spring Symposium.